The production and consumption of therapeutics have metamorphosed biopharma into a money-spinning industry that has achieved unprecedented growth. Therapeutics, in simple terms, is a device to counter the deficiencies present in an individual. Peptides are small chains of naturally occurring biological molecules called amino acids. They possess the ability to make the body imitate naturally occurring processes. Peptide therapeutics are in use owing to them being supremely efficacious. The use of peptide ranges from muscle boosting and anti-aging supplements to reviving the body from the slow metabolism that is a hallmark of endocrine disorders (Hypothyroidism and Obstructive Sleep Apnea). Retrieved from natural sources, these peptides have rescued countless lives since they were first introduced in the mid-20th century.
A well-known example is the dreaded insulin injections used by diabetics. When the pancreas is not able to produce sufficient amounts, insulin is externally injected under one’s skin. This helps balance the levels for the body to continue functioning properly. Recently, researchers have been focusing on creating pills that can bind to the stomach walls after oral administration, which would be life-altering for those who suffer from diabetes and endocrine disorders. A team of MIT scientists has been successful in creating such pills as a substitute for insulin injections, potentially rendering them useless.
With automation bounding ahead with mammoth steps, it has become crucial for humans to catch up and work in sync with the advancements in the industry. Discoveries such as peptides that would supposedly parry the attacks of a tumor are in progress, so are the previously mentioned oral pills, both of which show encouraging prospects for this industry. According to Reports and Data the Peptide Therapeutics Market was valued to be at USD 25.35 billion in 2018 and gives out strong indications of the market value almost doubling to USD 50.60 billion by the end of 2026, with a CAGR of 9.0%.
However, the success rates of research for some of these oral pills are going to be slow. The complication in this process is managing both the pancreatic and brush-border-enzymes (proteases), and the permeability of the intestinal epithelial layer. Ways to overcome these problems have been suggested and are, at present, under clinical testing. The dissimilitude in the dilution, intestinal transit time, gastric emptying, regional luminal pH, interplay with the contents of the intestine, and the formulation of a common solution proves to be difficult and takes time to surface.
The market for peptide therapeutics has sailed and escalated smoothly through the years. The increased number of cancer cases in 2018 corresponded with the growth of the respective products recorded in the year. Therefore, a high correlation between demand and growth is evident in this market. Due to the increasing dependence and acceptance of peptide drugs for revitalization, the market shows stable growth. North America holds the largest share (approximately 38%) in the peptide therapeutics global market. However, there is much faith, that soon the Asia Pacific region will be the chief contender for a bigger piece. The untapped opportunities of the past due to the lack of infrastructure and technological backwardness are anticipated to be rectified now and this would add to the size of the world market. Change (for the worse) in people’s lifestyles, gives out a predictable forecast of increased demand for peptide therapeutics. Owing to this, both Hybrid technology and metabolic disease segments have seen an identical growth of 8.8% and 8.9%, respectively.
Cancers, Metabolic Diseases, Cardiovascular Disorder, Respiratory, GIT, Anti-infection, Pain, Dermatology, CNS, and Renal, are some of the areas in which peptide therapeutics applications exist.
There are many players in this market, although only five out of those are currently dominant. Sanofi is a health care company whose researchers are working on finding a cure for even the rarest of diseases by using state-of-the-art technology. Another contender is Pfizer Inc. which is more than a century and a half old. The areas of interest of this company lie in immunizations and vaccinations against almost all kinds of health ailments that the human body is susceptible to. Another organization with similar objectives is the Switzerland-based Hoffmann-La Roche, which has been in existence since 1896. Other players currently holding major influence are Teva Pharmaceutical Industries Ltd from Israel and Takeda Pharmaceutical Company Ltd from Japan. The advancement of peptide therapeutics might sound as simple as shifting from injections to tablets to people who do not have to deal with such intricacies of illnesses, but for a patient, this switch would mean less pain, effort, and even expenses, which is a highly positive take on the market growth.
Author Bio –
Anjali Mishra is a content writer with a knack for all-things-market. She writes extensively for several industries including Reports and Data
Statements on this guest article reflect the market perspective of Reports and Data and do not represent our views and policies. GeneOnline News does not warrant or make any representations concerning the accuracy, likely results, or reliability of the use of the materials in this article.
Collaborate with us: [email protected]